Zentalis Pharmaceuticals (ZNTL) Profit After Tax (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Profit After Tax of -$35.4 million for Q1 2026, up 26.78% year-over-year from -$27.9 million in Q1 2025, and little changed quarter-over-quarter from -$35.2 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Profit After Tax (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 26.78% year-over-year to -$35.4 million; the TTM figure through Mar 2026 stood at -$124.1 million (up 44.64% YoY), while the FY2025 annual figure was -$137.1 million, up 17.37% from the prior year.
- Profit After Tax for Q1 2026 stood at -$35.4 million, roughly flat from -$35.2 million in the prior quarter.
- The five-year high for Profit After Tax was $10.0 million in Q1 2024, with the low at -$112.6 million in Q2 2023.
- The 5-year median for Profit After Tax is -$54.4 million (2022), against an average of -$51.0 million.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax tumbled 1198.04% in 2022, then soared 115.88% in 2024.
- Zentalis Pharmaceuticals' Profit After Tax stood at -$55.0 million in 2022, then fell by 10.86% to -$60.9 million in 2023, then grew by 22.05% to -$47.5 million in 2024, then gained by 25.86% to -$35.2 million in 2025, then dropped by 0.39% to -$35.4 million in 2026.
- Business Quant data shows ZNTL's Profit After Tax at -$35.4 million in Q1 2026, -$35.2 million in Q4 2025, and -$26.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | -42.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.29 Mn |
| Mar 31, 2026 | -35.35 Mn |
| Dec 31, 2025 | -35.22 Mn |
| Sep 30, 2025 | -26.69 Mn |
| Jun 30, 2025 | -26.87 Mn |
| Mar 31, 2025 | -48.28 Mn |
| Dec 31, 2024 | -47.50 Mn |
| Sep 30, 2024 | -40.16 Mn |
| Jun 30, 2024 | -88.28 Mn |
| Mar 31, 2024 | 10.04 Mn |
| Dec 31, 2023 | -60.94 Mn |
| Sep 30, 2023 | -55.53 Mn |
| Jun 30, 2023 | -112.56 Mn |
| Mar 31, 2023 | -63.22 Mn |
| Dec 31, 2022 | -54.97 Mn |
| Sep 30, 2022 | -54.40 Mn |
| Jun 30, 2022 | -68.39 Mn |
| Mar 31, 2022 | -59.24 Mn |
| Dec 31, 2021 | -50.06 Mn |
| Sep 30, 2021 | -4.19 Mn |